First-pass contrast-enhanced magnetic resonance angiography in humans using ferumoxytol, a novel ultrasmall superparamagnetic iron oxide (USPIO)-based blood pool agent

Journal of Magnetic Resonance Imaging

Volumn 21, Issue 1, 2005, Pages 46-52

  Li, Wei ^a,d,e   Tutton, Sean ^a   Vu, Anthony T ^b   Pierchala, Linda ^a   Li, Belinda S Y ^b,d   Lewis, Jerome M ^c   Prasad, Pottumarthi V ^a   Edelman, Robert R ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b GE HEALTHCARE   (United States)

^c Advanced Magnetics Inc   (United States)

^d Advanced Magnetics Inc ^*  (United States)

^e EVANSTON HOSPITAL   (United States)

Author keywords

Blood pool contrast agent; Contrast enhanced MR angiography; Ferumoxytol; First pass; Intravascular contrast agent; Magnetic resonance imaging

Indexed keywords

CONTRAST MEDIUM; FERUMOXYTOL; GADOLINIUM PENTETATE; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE;

ABDOMINAL AORTA; ADULT; AGED; ANGIOGRAPHY; AORTA ANEURYSM; ARTICLE; CAROTID ARTERY; CAROTID ARTERY DISEASE; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; DIAGNOSTIC IMAGING; FEMALE; HUMAN; KIDNEY ARTERY STENOSIS; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; NORMAL HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PERIPHERAL VASCULAR DISEASE; PHANTOM; PRIORITY JOURNAL; SIGNAL NOISE RATIO; THORACIC AORTA; THREE DIMENSIONAL IMAGING; VASCULAR DISEASE; VEIN MALFORMATION;

ADULT; AGED; AGED, 80 AND OVER; CONTRAST MEDIA; FEMALE; FERROSOFERRIC OXIDE; HUMANS; IRON; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; MIDDLE AGED; OXIDES; PHANTOMS, IMAGING;

EID: 11144347685     PISSN: 10531807     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmri.20235     Document Type: Article

References (32)

1. Prince MR. Gadolinium-enhanced MR aortography. Radiology 1994;191:155-164.
2. Yucel EK. MR angiography for evaluation of abdominal aortic aneurysm: has the time come? Radiology 1994;192:321-323.
3. McLachlan SJ, Morris MR, Lucas MA, et al. Phase I clinical evaluation of a new iron oxide MR contrast agent. J Magn Reson Imaging 1994;4:301-307.
4. Mitchell DG. MR imaging contrast agent - what's in a name? J Magn Reson Imaging 1997;7:1-4.
5. Lauffer R, Parmlee D, Dunham S, et al. MS-325: albumin-targeted contrast agent for MR angiography. Radiology 1998;207:529-538.
6. Knopp MV, Tengg-Kobligk HV, Floemer F, Schoenberg SO. Contrast agents for MRA: future directions. J Magn Reson Imaging 1999;10: 314-316.
7. Kroft LJM, Roos AD. Blood pool contrast agent for cardiovascular MR imaging. J Magn Reson Imaging 1999;10:395-403.
8. Mayo-Smith WW, Saini S, Slater G, Kaufman JA, Sharma P, Hahn PF. MR contrast material for vascular enhancement: value of superparamagnetic iron oxide. AJR Am J Roentgenol 1996;166:73-77.
9. Reimer P, Allkemper T, Matuszewski L, Balzer T. Contrast-enhanced 3D-MRA of the upper abdomen with a bolus-injectable SPIO (SH U 555). J Magn Reson Imaging 1999;10:65-71.
10. Korosec FR, Turski PA, Carroll TJ, Mistretta CA, Grist TM, Mistretta CA. Contrast-enhanced MR angiography of the carotid bifurcation. J Magn Reson Imaging 1999;10:317-325.
11. Kellar KE, Fujii DK, Gunther WHH, et al. NC100150 injection, a preparation of optimized iron oxide nanoparticles for positive-contrast MR angiography. J Magn Reson Imaging 2000;11:488-494.
12. Bunce NH, Moon JC, Bellenger NG, et al. Improved cine cardiovascular magnetic resonance using Clariscan (NC100150 injection). J Cardiovasc Magn Reson 2001;16:217-223.
13. Bunce NH, Keegan J, Gatehouse PD, et al. Initial experience with the intravascular contrast agent NC100150-injection (Clariscan®) for breath-hold and navigator-gated magnetic resonance coronary artery imaging. J Magn Reson Imaging 2002;10:404-410.
14. Stillman AE, Wilke N, Li D, Haacke M, McLachlan S. Ultrasmall superparamagnetic iron oxide to enhance MRA of the renal and coronary arteries: studies in human patients. J Comput Assist Tomogr 1996;20:51-55.
15. Anzai Y, Prince MR, Chenevert TL, et al. MR angiography with an ultrasmall superparamagnetic iron oxide blood pool agent. J Magn Reson Imaging 1997;7:209-214.
16. Loubeyre P, Zhao S, Canet E, et al. Ultrasmall superparamagnetic iron oxide particles (AMI 227) as a blood pool contrast agent for MR angiography: experimental study in rabbits. J Magn Reson Imaging 1997;7:958-962.
17. Knollmann FD, Böck JC, Teltenkötter S, et al. Evaluation of portal MR angiography using superparamagnetic iron oxide. J Magn Reson Imaging 1997;7:191-196.
18. Zheng J, Carr J, Harris K, et al. Three-dimensional MR pulmonary perfusion imaging and angiography with an injection of a new blood pool contrast agent B-22956/1. J Magn Reson Imaging 2001;14: 425-432
19. Hoffmann U, Loewe C, Bernhard C, et al. MRA of the lower extremities in patients with pulmonary embolism using a blood pool contrast agent: initial experience. J Magn Reson Imaging 2002;15: 429-437.
20. Grist TM, Korosec FR, Peters DC, et al. Steady-state and dynamic MR angiography with MS-325: initial experience in humans. Radiology 1998;207:539-544.
21. Frank H, Weissleder R, Brandy TJ. Enhancement of MR angiography with iron oxide: preliminary studies in whole blood phantom and in animals. AJR Am J Roentgenol 1994;162:209-213.
22. Taupitz M, Schnorr J, Abramjuk C, et al. New generation of monomer-stabilized very small superparamagnetic iron oxide particles (VSOP) as contrast medium for MR angiography: preclinical results in rats and rabbits. J Magn Reson Imaging 2000;12:905-911.
23. Taupitz M, Schnorr J, Wagner S, et al. Coronary MR angiography: experimental results with a monomer-stabilized blood pool contrast medium. Radiology 2002;222:120-126
24. Schnorr J, Wagner S, Abramjuk C, et al. Comparison of the iron-oxide-based blood-pool contrast medium VSOP-C184 with Gd-DTPA in first-pass MRA of the aorta and renal arteries in pigs. In: Proceedings of the 11th Annual Meeting of ISMRM. Toronto, Canada. 2003. p 1337.
25. Dirksen MS, Kaandorp TAM, Lamb HJ, Doornbos J, Corot C, Roos AD. Three-dimensional navigator coronary MRA with the aid of a blood pool agent in pigs: improved image quality with inclusion of the contrast agent first-pass. J Magn Reson Imaging 2003;18:502-506.
26. Tombach B, Reimer P, Mahler M, Ebert W, Pering C, Heindel W. First-pass and equilibrium phase MRA following intravenous bolus injection of SH U 555 C: phase I clinical trial in elderly volunteers with risk factors for arterial vascular disease. Acad Radiol 2002; 9(Suppl 2):S425-S427.
27. Reimer P, Bremer C, Allkemper T, et al. Myocardial perfusion and MR angiography of chest with SH U 555 C: result of placebo-controlled clinical phase I study. Radiology 2004;231:474-481.
28. Prasad PV, Pierchala L, Chen Q, Vu A, Li W, Lewis J, Edelman RR. Preliminary evaluation of code 7228 as an iron oxide based blood pool contrast agent for CE-MRA. In: Proceedings of the 11th Annual Meeting of ISMRM. Toronto, Canada, 2003. p 1338.
29. Prince MR, Zhang HL, Chabra SG, Jacobs P, Wang Y. A pilot investigation of new superparamagnetic iron oxide (ferumoxytol) as a contrast agent for cardiovascular MR1. J X-ray sci technol 2003; 11:231-240.
30. Ersoy H, Jacobs P, Kent CK, Prince MR. Blood pool MR Angiography of aortic stent-graft endoleak. AJR Am J Roentgenol 2004;182: 1181-1186.
31. Jacobs P, Shenouda M. A phase 1 pharmacokinetics and safety study of ferumoxytol: a new blood pool and macrophage specific superparamagnetic iron oxide MR contrast agent. In: Proceedings of the 89th Scientific Assembly and Annual Meeting of the Radiological Society of North America. Chicago. 2003. p 249.
32. Korosec FR, Frayne R, Grist TM, Mistretta CA. Time-resolved contrast-enhanced 3D MR angiography. Magn Reson Med 1996;36: 345-351.